<table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" id="table2" position="float"><object-id pub-id-type="doi">10.7554/eLife.37294.011</object-id><label>Table 2.</label><caption><title>Tumor CNA burden is associated with recurrence and overall survival independent of disease stage in multiple cancer types</title></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"><italic>Cohort</italic></th><th rowspan="2"><italic>Model</italic></th><th colspan="4" valign="top"><italic>Disease free Time</italic></th><th colspan="4" valign="top"><italic>Overall Survival</italic></th></tr><tr><th valign="top">Cases</th><th valign="top">HR</th><th valign="top">95% CI</th><th valign="top">P</th><th valign="top">Cases</th><th valign="top">HR</th><th valign="top">95% CI</th><th colspan="2" valign="top">P</th></tr></thead><tbody><tr><td rowspan="2" valign="top">Prostate cancer TCGA</td><td>Tumor CNA burden, per 5% tumor CNA burden, univariate</td><td>280</td><td>1.27</td><td>1.13, 1.42</td><td>&lt;0.0001</td><td colspan="4" rowspan="4">Insufficient events <break/> <break/><break/></td></tr><tr><td>Tumor CNA burden, per 5% tumor CNA burden, adjusted for Gleason grade and mutation burden</td><td>279</td><td>1.18</td><td>1.03, 1.35</td><td>0.015</td></tr><tr><td/><td>Tumor CNA burden, per 5% tumor CNA burden, adjusted for purity (ABSOLUTE)*</td><td>243</td><td>1.22</td><td>1.07, 1.40</td><td>0.003</td></tr><tr><td/><td>Tumor CNA burden, per 5% tumor CNA burden, adjusted for ploidy</td><td>243</td><td>1.32</td><td>1.11, 1.56</td><td>0.002</td></tr><tr><td rowspan="2" valign="top">Breast cancer TCGA</td><td>Tumor CNA burden, per 5% tumor CNA burden, univariate</td><td>709</td><td>1.07</td><td>1.01, 1.14</td><td>0.028</td><td>794</td><td>1.08</td><td>1.03, 1.13</td><td>0.0005</td></tr><tr><td>Tumor CNA burden, per 5% tumor CNA burden, Multivariable, adjusted for disease stage</td><td>695</td><td>1.07</td><td>1.00, 1.14</td><td>0.049</td><td>777</td><td>1.08</td><td>1.03, 1.13</td><td>0.002</td></tr><tr><td rowspan="2" valign="top">Endometrial Cancer TCGA</td><td>Tumor CNA burden, per 5% tumor CNA burden, univariate</td><td>496</td><td>1.10</td><td>1.06, 1.14</td><td>&lt;0.0001</td><td>536</td><td>1.13</td><td>1.08, 1.17</td><td>&lt;0.0001</td></tr><tr><td>Tumor CNA burden, per 5% tumor CNA burden, multivariable, adjusted for disease stage</td><td>496</td><td>1.08</td><td>1.04, 1.13</td><td>&lt;0.0001</td><td>536</td><td>1.10</td><td>1.05, 1.15</td><td>&lt;0.0001</td></tr><tr><td rowspan="2" valign="top">Renal clear cell cancer TCGA</td><td>Tumor CNA burden, per 5% tumor CNA burden, univariate</td><td>425</td><td>1.05</td><td>1.01, 1.09</td><td>0.028</td><td>525</td><td>1.02</td><td>0.98, 1.06</td><td>NS (0.4)</td></tr><tr><td>Tumor CNA burden, per 5% tumor CNA burden, multivariable, adjusted for disease stage</td><td>423</td><td>1.05</td><td>1.00, 1.11</td><td>0.035</td><td>522</td><td>1.01</td><td>0.97, 1.06</td><td>NS (0.7)</td></tr><tr><td rowspan="2" valign="top">Thyroid cancer TCGA</td><td>Tumor CNA burden, per 5% tumor CNA burden, univariate</td><td>483</td><td>1.17</td><td>1.01, 1.35</td><td>0.033</td><td>497</td><td>1.30</td><td>1.04, 1.63</td><td>0.021</td></tr><tr><td>Tumor CNA burden, per 5% tumor CNA burden, multivariable, adjusted for disease stage</td><td>481</td><td>1.18</td><td>1.00, 1.39</td><td>0.048</td><td colspan="4">Insufficient events</td></tr><tr><td rowspan="2" valign="bottom">Colorectal cancer TCGA</td><td>Tumor CNA burden, per 5% tumor CNA burden, univariate</td><td>512</td><td>1.05</td><td>1.00, 1.11</td><td>0.037</td><td>587</td><td>1.06</td><td>1.01, 1.12</td><td>0.012</td></tr><tr><td>Tumor CNA burden, per 5% tumor CNA burden, multivariable, adjusted for disease stage</td><td>496</td><td>1.03</td><td>0.98, 1.09</td><td>NS (0.3)</td><td>567</td><td>1.03</td><td>0.97, 1.09</td><td>NS (0.3)</td></tr><tr><td valign="bottom"/><td>Tumor CNA burden, per 5% tumor CNA burden, multivariable, adjusted for tumor stage</td><td>511</td><td>1.06</td><td>1.01, 1.12</td><td>0.028</td><td>585</td><td>1.07</td><td>1.02, 1.13</td><td>0.009</td></tr></tbody></table><table-wrap-foot><fn><p>*Result differed with similar adjustment in IMPACT prostate cancer cohort utilizing FACETS, see <xref ref-type="supplementary-material" rid="supp2">Supplementary file 3</xref>.</p></fn></table-wrap-foot></table-wrap>